(PharmaNewsWire.Com, November 05, 2020 ) Research Methodology Followed in This Study:
Top-down and bottom-up approaches were used to validate the size of the global Antibody Production Technology Market and estimate the size of various other dependent submarkets. Various secondary sources such as directories, industry journals, databases such as Hoover’s, Bloomberg Business, Factiva, and Avention, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market.
The antibody production market comprises products that are required during the different stages of bioprocessing of antibodies, such as upstream processing, downstream processing, and filtration.
Expected Growth in Revenue:
The global Antibody Production Market is projected to reach USD 13.28 Billion by 2021 from USD 7.45 Billion in 2016, at a CAGR of 12.3% during the forecast period of 2016 to 2021.
The improved approval rate of therapeutic antibodies by regulatory authorities, patent expiry of blockbuster monoclonal antibodies, increasing adoption of targeted immunotherapy, and increased R&D expenditure of pharmaceutical and biotechnology companies are driving the overall market. The increasing prevalence of infectious diseases and rising demand for protein therapeutics are expected to provide growth opportunities for players operating in Antibody Production Technology Market.
End Users:
On the basis of end user, the antibody production market is segmented into pharmaceutical and biotechnology companies, research institutes, and diagnostic laboratories. The pharmaceutical and biotechnology companies segment is expected to account for the largest share of the market in 2016, and is projected to register the highest CAGR during the forecast period.
Geographical Growth Scenario:
Geographically, the global antibody production market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America, Middle East, and Africa). North America is expected to account for the largest share of the antibody production market in 2016, followed by Europe. The Asia-Pacific region offers significant growth opportunities for companies offering antibody production products, and is projected to grow at the highest CAGR during the forecast period.
Global Leaders:
The Antibody Production Technology Market comprises several players such as GE Healthcare (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), Pall Corporation (U.S.), Sigma-Aldrich Corporation (Germany), Eppendorf AG (Germany), Cellab GmbH (Germany), INTEGRA Biosciences AG (Switzerland), and FiberCell Systems Inc. (U.S.).
New product launches; expansions; agreements, alliances, collaborations, and partnerships; mergers and acquisitions; and others (new service launches, product enhancements, and spin-offs) are the major strategies followed by players to achieve growth in this market. New product launches accounted for ~51% of the total developments undertaken by the players in this market. The key players that adopted this strategy are Eppendorf AG (Germany), Sartorius AG (Germany), Merck KGaA (Germany), GE Healthcare (U.S.), and Agilent Technologies, Inc. (U.S.).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
